HLB Global: Merger completion report filed

Merger process finalized

An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).

HLB Global plunges as weak sentiment and outflows hit the biotech sector.

Selling in biotech intensified as investors questioned R&D spending and demanded proof of earnings, with foreign investors and institutions both dumping shares, and the stock fell sharply as the lack of concrete results such as licensing deals or earnings weighed on sentiment.

• 10.01 ★★ Report on major shareholding
• 09.14 ★★★ Plans ₩5bn convertible bond offering for working capital